Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.73 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.52 |
| ▸ | GABRP | O00591 | 3/20 | 0.52 |
| ▸ | GABRD | O14764 | 3/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.52 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.52 |
| ▸ | GABRE | P78334 | 3/20 | 0.52 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.52 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.52 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.52 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7005455 | 0.90 | SRD5A2 (0.59) | SRD5A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL7004252 | 0.89 | SRD5A2 (0.58) | SRD5A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL6595625 | 0.88 | SRD5A2 (0.77) | SRD5A2KDM4EALDH1A1RAB9ANPC1 | |
| SCHEMBL6804626 | 0.87 | SRD5A2 (0.55) | SRD5A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL3043331 | 0.87 | SRD5A2 (0.55) | SRD5A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL30024037 | 0.87 | SRD5A2 (0.55) | SRD5A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL7006504 | 0.87 | SRD5A2 (0.56) | SRD5A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL914178 | 0.85 | SRD5A2 (0.54) | SRD5A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL27189535 | 0.85 | SRD5A2 (0.53) | SRD5A2GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL30397127 | 0.85 | SRD5A2 (1.00) | SRD5A2KDM4EALDH1A1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-12-09 | — | — | US | disclosed |
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED | 2021-12-09 | — | — | US | disclosed |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-11-07 | — | — | US | disclosed |
| US-10370388-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2019-08-06 | — | — | US | disclosed |
| WO-2018134731-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-26 | — | — | WO | disclosed |
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-05-25 | — | — | US | disclosed |
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-05-25 | — | — | US | disclosed |
| US-9624243-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-9624243-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-12-25 | — | — | US | disclosed |
| EP-1200439-B1 | 1,2-DIHYDRO-1-OXO-PARAZINO(1,2-A) INDOLE DERIVATIVES | NOVUSPHARMA SPA (IT) | 2003-06-25 | — | — | EP | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1230218-A1 | POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS | AstraZeneca AB (SE) | 2002-08-14 | — | — | EP | disclosed |
| EP-1200439-A1 | 1,2-DIHYDRO-1-OXO-PARAZINO(1,2-A) INDOLE DERIVATIVES | Novuspharma S.p.A. (IT) | 2002-05-02 | — | — | EP | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
| US-6337344-B1 | ANTICOAGULANTS AND ENZYME INHIBITORS FOR CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-08 | — | — | US | disclosed |
| WO-2001032622-A1 | POSITIVE MODULATORS OF NICOTINIC RECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2001-05-10 | — | — | WO | disclosed |
| WO-2001009136-A1 | 1,2-DIHYDRO-1-OXO-PYRAZINO[1,2-A]INDOLE DERIVATIVES | NOVUSPHARMA S.P.A. (IT) | 2001-02-08 | — | — | WO | disclosed |
| EP-1042287-A1 | INDOLE DERIVATIVES AS INHIBITORS OF FACTOR XA | Aventis Pharma Deutschland GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999033800-A1 | INDOLE DERIVATIVES AS INHIBITORS OR FACTOR XA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370388-B2 | Heterocyclic compounds and methods of their use | AGTR2, AGTR1, BDKRB2 | SRD5A2 3387/4885GABRA1 1127/4885GABRG2 1106/4885 |
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | AGTR2, AGTR1, BDKRB2 | SRD5A2 3352/4885GABRA1 1125/4885GABRG2 1115/4885 |
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | AGTR2, AGTR1, BDKRB2 | SRD5A2 3352/4885GABRA1 1125/4885GABRG2 1115/4885 |
| US-20210379044-A1 | NON PEPTIDIC HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | SRD5A2 4300/4885GABRA1 423/4885GABRG2 624/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | SRD5A2 1097/4885GABRA1 410/4885GABRG2 1689/4885 |
| US-20190336489-A1 | NON PEPTIDE HETEROBIVALENT MOLECULES FOR TREATING INFLAMMATORY DISEASES | ACKR3, CXCR3, CCL2 | SRD5A2 4417/4885GABRA1 412/4885GABRG2 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.